ADM has announced the publication of a clinical study investigating the effects of PRIOME Metabolic Health (PRIOME MH), in both probiotic and heat-treated postbiotic form in adult dogs.
Published in the journal Animals, this study contributes to ADM's postbiotic evidence base and highlights PRIOME MH within ADM's expanding pet biotics portfolio.
Why this matters
Metabolic health plays a crucial role in determining both longevity and quality of life in dogs.
It includes important factors such as weight management, blood glucose regulation and hormonal balance.
While healthy dogs usually regulate their blood sugar effectively, recurring spikes in glucose (especially in overweight or older dogs) can lead to insulin resistance and other metabolic issues.
Led by Dr Sophie Nixon, Head of Clinical Research for Pet and Animal Wellbeing, the clinical trial demonstrated the potential role of PRIOME MH postbiotic to support canine metabolic health.
The randomised, double-blind, placebo-controlled clinical study was conducted in 45 healthy adult dogs, evaluating the impact of daily probiotic or postbiotic supplementation on metabolic health markers during periods of induced weight gain and weight loss.
During the weight-loss phase of the trial, dogs receiving PRIOME MH demonstrated a significant reduction in postprandial blood glucose compared with dogs given a placebo.
This trial adds to the growing body of evidence on postbiotics in companion animal research and promotes innovation in functional nutrition.
The findings significantly improve the industry's understanding of how postbiotics can be applied to support canine metabolic health, an area that has traditionally been overlooked in biotic ingredient development.